CAP-1002 is a Cell Therapy owned by Capricor Therapeutics, and is involved in 8 clinical trials, of which 5 were completed, and 3 are ongoing.

CAP-1002 is a restorative mixture comprising a family of heart-derived stem cells. These cells provide mutual support and structure for each other and are more effective in improving cardiac function than other isolated cell types. When injected into the body, these cells lead to the formation of new cardiomyocytes, vascular endothelium, and smooth muscle cells, generating de novo myocardium, including coronary arteries, arterioles, and capillaries. CAP-1002 acts by decreasing infarct size in myocardial infarction and ischemic left ventricular dysfunction.

The revenue for CAP-1002 is expected to reach a total of $2.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the CAP-1002 NPV Report.

CAP-1002 is originated and owned by Capricor Therapeutics.

CAP-1002 Overview

CAP-1002 is under development for the treatment of pulmonary arterial hypertension, advanced heart failure, Duchenne muscular dystrophy, ischemic heart disease, coronavirus disease 2019 (COVID-19). CDCs are delivered by intravenous and intracoronary infusion. The drug candidate is allogeneic cardiosphere-derived stem cells (CDCs). The drug candidate is developed based on CDC technology. It was also under development for the treatment of dilated cardiomyopathy, myocardial infarction, cardiomyopathy and ischemic left ventricular dysfunction. The drug candidate is a new molecular entity (NME).

Capricor Therapeutics Overview

Capricor Therapeutics (Capricor) is a biotechnology company that focuses on the development and commercialization of biological therapies for the treatment of duchenne muscular dystrophy (DMD) and other rare disorders. The company pipeline product includes CAP-1002 is an allogeneic cardiosphere-derived cell product for the treatment of adult cardiology indications. Capricor technology comprises CAP-2003 for clinical development. The company is developing its exosome technologies as a next generation platform in a variety of diseases. The company offers research programs on cell therapy, natriuretic peptides and exosome platforms. It also conducts clinical trials for the development of novel therapeutics to prevent and treat cardiac and other serious medical conditions. Capricor is headquartered in San Diego, California, the US.

The company reported revenues of (US Dollars) US$0.3 million for the fiscal year ended December 2021 (FY2021), a decrease of 21% over FY2020. The operating loss of the company was US$20.6 million in FY2021, compared to an operating loss of US$13.7 million in FY2020. The net loss of the company was US$20 million in FY2021, compared to a net loss of US$13.7 million in FY2020.

Quick View – CAP-1002

Report Segments
  • Innovator
Drug Name
  • CAP-1002
Administration Pathway
  • Intracoronary
  • Parenteral
Therapeutic Areas
  • Cardiovascular
  • Genetic Disorders
  • Infectious Disease
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.